Perimenopause — How Early Can It Start? (And What to Do About It)
Most women think of menopause as something that happens in their early 50s. A clear transition. A defined moment. Something they'll know when it arrives.
The reality is considerably more complicated — and considerably earlier.
Perimenopause, the hormonal transition that precedes menopause, can begin in a woman's late 30s or early 40s. Sometimes earlier. The median duration is four years, but for many women it stretches to eight or ten. And here is what makes this particularly frustrating: the symptoms that arrive during this transition are frequently attributed to everything except the actual cause — stress, anxiety, depression, burnout, insomnia, weight gain from poor habits, or simply getting older.
You are not imagining it. And you are not just getting older.
What Perimenopause Actually Is
Menopause is defined as twelve consecutive months without a menstrual period. Everything before that point — which can span years of hormonal fluctuation — is perimenopause.
The distinction matters clinically because perimenopause is not a low-estrogen state. That's a common misconception. In the early stages, estrogen often fluctuates widely — sometimes surging higher than normal before dropping. This unpredictability is what produces many of the most disruptive symptoms. The hormonal signal isn't steady and declining; it's erratic. And the brain, the nervous system, the sleep architecture, and the mood regulation systems all feel it.
What's actually happening biologically: as the number of remaining ovarian follicles declines, the communication between the pituitary gland and the ovaries becomes less predictable. FSH — the hormone that signals the ovaries to develop follicles — begins rising as the ovaries become less responsive. The result is cycle irregularity, hormonal surges and drops, and a constellation of symptoms that can arrive years before any obvious change in menstrual pattern.
The Symptoms Nobody Warned You About
Hot flashes get the most attention. They're the symptom most commonly associated with menopause, and for many women they're significant. But hot flashes are not the primary driver of suffering for most women in perimenopause. The symptoms that affect quality of life most deeply — according to current clinical research — are the ones that are most easily attributed to something else.
Mood changes. Perimenopausal women have a two to four times higher risk of new-onset depression compared to premenopausal women. New-onset anxiety — appearing in women who have never been particularly anxious before — is one of the most common presentations I hear described. "I have never been anxious but now I worry about everything" is a sentence I have heard in some form more times than I can count. This is not a personality change. It is a neurological effect of fluctuating estrogen and progesterone on neurotransmitter systems — specifically serotonin, dopamine, and GABA.
Hormone therapy is on par with antidepressants and anti-anxiety medications for mood symptoms in perimenopausal women. That is not fringe medicine. That is the current clinical evidence.
Sleep disruption. The 2 to 4am waking pattern that appears during perimenopause — waking in the middle of the night, often with a racing mind or sense of unease, unable to fall back asleep — is one of its most consistent features. It's driven by the cortisol dysregulation and progesterone loss that occur during the transition. Progesterone acts directly on GABA receptors in the brain — the same receptors targeted by sleep medications and anti-anxiety drugs. When progesterone declines, the brain loses a natural calming influence that most women never knew they had until it was gone.
Brain fog and cognitive changes. "I think I have early onset dementia" is something women say to me — sometimes half-jokingly, sometimes with genuine fear. Difficulty with word recall, slower processing, loss of mental sharpness — these are real, they are common, and they are hormonal. Estrogen has direct effects on neurogenesis, synaptic plasticity, and the neurotransmitter systems that support cognitive function. When estrogen fluctuates unpredictably, the brain notices.
Body composition changes. Research shows that visceral fat — the metabolically active fat stored around the organs and abdomen — represents 5 to 8 percent of total body fat in premenopausal women. In postmenopausal women, that figure rises to 15 to 20 percent. The shift begins during perimenopause and is driven by multiple mechanisms: declining estrogen, rising cortisol, changes in insulin sensitivity, and loss of lean muscle as anabolic hormone levels fall. This explains why women in perimenopause frequently experience weight gain around the middle that resists every intervention they've tried before.
Joint pain and musculoskeletal symptoms. This one surprises most women. Musculoskeletal symptoms affect 50 to 70 percent of women during the menopausal transition — joint stiffness, diffuse aches, reduced tendon and ligament resilience. Estrogen has direct effects on cartilage, synovial tissue, and the inflammatory processes that govern joint health. Its decline during perimenopause is directly linked to the joint symptoms that so many women attribute to age, overuse, or just "how my body is now."
Changes in libido and sexual health. Testosterone, which begins declining in women in their late 20s, often reaches levels that produce noticeable effects on sexual desire during perimenopause. Combined with fluctuating estrogen affecting vaginal tissue and arousal, many women experience changes in their sexual health that feel confusing and isolating — and that are almost never addressed proactively by their healthcare providers.
You Don't Need Hot Flashes to Start Treatment
This is one of the most important clinical points in the current perimenopause literature, and it's one that conventional medicine has been slow to communicate to patients.
You do not need vasomotor symptoms — hot flashes, night sweats — to have perimenopause. You do not need cycle irregularity to have perimenopause. And you do not need either of those things to benefit from hormone therapy.
Current evidence-based menopause medicine is clear: treatment decisions should be based on symptoms and quality of life — not on whether a specific symptom type is present or a specific lab threshold has been crossed. A woman in her early 40s who is experiencing significant mood disruption, sleep dysfunction, cognitive changes, and body composition shifts consistent with perimenopausal transition is a candidate for a clinical evaluation and a thoughtful conversation about her options — even if she hasn't had a single hot flash.
The earlier that evaluation happens, the more options are available and the less accumulated impact there is on bone density, cardiovascular health, cognitive function, and metabolic stability — all of which have long-term trajectories that begin during the perimenopausal transition.
A Note on the FDA's Updated Position
In November 2025, the FDA recommended removing the black box warnings that had been attached to hormone therapy for decades — specifically the warnings related to blood clots, cardiovascular disease, invasive breast cancer, and dementia. These warnings were the legacy of the original 2002 WHI study, applied to a population and formulation that didn't represent most women who would benefit from hormone therapy.
This is a meaningful regulatory update that reflects two decades of additional research. The clinical guidance from menopause medicine specialists has been ahead of this for years — but the regulatory change matters because it changes what patients are told and removes a barrier that has kept too many women from accessing care that could help them.
This doesn't mean hormone therapy is appropriate for everyone. There are genuine contraindications that require individual evaluation. But it does mean the conversation deserves to happen — and the fear-based framework that defined it for twenty years is being officially retired.
What an Evaluation at NOVA Looks Like
When a woman comes in with symptoms consistent with perimenopause — regardless of age, regardless of whether her cycle is irregular, regardless of whether she's having hot flashes — we start with a full picture.
That means a comprehensive hormone panel: estradiol, progesterone, FSH, LH, total and free testosterone, SHBG, full thyroid panel, DHEA-S, cortisol, and key metabolic markers. It means a real conversation about symptoms, history, family history, and goals. And it means building a plan specific to her — not a standard protocol applied uniformly.
Sometimes that plan includes hormone therapy. Sometimes it begins with addressing thyroid, insulin resistance, cortisol, or nutritional deficiencies that are amplifying the perimenopausal picture. Sometimes it's a combination. There is no template. There is only your situation, your labs, and what makes clinical sense for you.
What I want women who read this to take away is simple: if you are in your late 30s or 40s and something has shifted — your sleep, your mood, your energy, your body, your mind, your sense of yourself — you are not too young for this conversation. You are exactly the right age for it.
Book a free 30-minute consultation at novawellnessut.com or call and text us at (801) 449-1402.
Matt Nelson, NP
NOVA Wellness — Orem, Utah
(801) 449-1402 · novawellnessut.com
